Back to Search
Start Over
Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin
- Source :
- Therapy. 7:555-563
- Publication Year :
- 2010
- Publisher :
- OMICS Publishing Group, 2010.
-
Abstract
- Micafungin is one of three echinocandin antifungals approved by the US FDA and the European Medicines Agency (EMA). Like all echinocandin antifungals, micafungin inhibits the synthesis of 1,3-β-D-glucan, a main component of the cell wall of many medically important fungi; thus, exerting fungicidal activity against most Candida spp., as well as fungistatic activity against many Aspergillus spp. Micafungin displays linear pharmacokinetics over the therapeutic range with a long half-life, allowing once-daily intravenous administration. Steady state serum concentrations are achieved after 3 days. Since therapeutic concentrations of micafungin are achieved after the administration of a standard dose there is no need for a loading dose. Interactions of micafungin with the cytochrome P450 (CYP3A4) system are marginal; and, consequently, no severe drug–drug interactions have been reported so far. Furthermore, micafungin exhibited favorable profiles for tolerability and safety; no dose-limiting toxicity has been e...
Details
- ISSN :
- 1744831X and 14750708
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Therapy
- Accession number :
- edsair.doi...........bd59b6f1620030700cdeb94533d5d975